NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Reta-Peptide

Published 12 Nov 2026. 38-page investigative report on who is behind Reta-Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 5 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Reta-Peptide is not a simple pass/fail vendor. Across 266 Finnrick lab tests, the overall record is 198 pass / 67 fail, a 74% pass rate. The spread is wide: GHK-Cu and Tirzepatide test strongly, Retatrutide has meaningful depth but a fill-mass caveat in the marketplace record, and TB-500 sits in the avoid-or-test-first tier. The full product chart and stricter-grading view matter because the stronger lines do not rescue the weaker ones.

The investigation also separates two channels buyers often treat as interchangeable. The direct Reta-Peptide site is a static Shopify catalog with private ordering by sales contact, wire/crypto payment, Janoshik links, and no public batch-to-vial verifier. Retalux on Peptaura is more auditable, with PPA-RL batch tokens, a public verifier, COAs, reviews, and escrow; that does not automatically authenticate direct-site vials.

Identity and control remain the bigger non-lab question. RDAP, Echemi, site source, and archived privacy records point to mainland China operations in Zhejiang and Henan, while no U.S. legal entity was found in the public sources reviewed. The About page claims an owned lab and production line, but Echemi classifies the business as a Trader, and no named QA, analytical, or batch-release authority could be established from the reviewed public record.

Several operational details sharpen the buyer read: the privacy policy removed a Zhengzhou address and now gives no entity or postal address; the direct COA page appears static; a Retalux verifier can pass while still showing material overfill; and the brand sits amid lookalike domains, SEO-spam traces, and impersonation warnings without a public whitelist.

Inside the full report:

  • Appendix A with per-product Finnrick pass/fail rates, rating trajectories, and methodology-divergence charts for all 15 tested products
  • RDAP, DNS, Shopify, Echemi, and archived privacy-policy exhibits mapping operating geography and entity gaps
  • Direct-site catalog, price, COA-link, ordering, payment, refund, and quality-claim analysis
  • Retalux/Peptaura marketplace teardown: PPA-RL batch tokens, verifier fields, COA entries, escrow, reviews, and recall-language
  • ILS certificate review for two buyer-submitted Retalux lots and the limits of those lot-specific positives
  • Brand-confusion map covering lookalike domains, SEO-spam pages, the RETA LUXE claim, and the deleted X promoter account

Risk assessment

  • Product-specific quality risk — BPC-157, Tesamorelin, TB-500, MOTS-c, CJC-1295, NAD+ — high: Finnrick ratings are weak for these lines: BPC-157 52.43%, Tesamorelin 49.99%, TB-500 37.96%, MOTS-c 39.9%, CJC-1295 31.56%, and NAD+ 27.96%; avoid or independently test exact lots.
  • Retatrutide fill-mass variance risk — medium: Retatrutide is comparatively strong overall at 84.8%, but Peptaura batch PPA-RL-RT30-R00222 shows 33.94 mg in a 30 mg vial, or 113.133% of label, while marked Pass/Bronze.
  • Counterparty identity and UBO opacity risk — high: No legal entity, beneficial owner, director, shareholder, or registered counterparty was identified; current privacy policy names no entity or postal address.
  • Manufacturer-claim and technical-control transparency risk — high: The site claims its own lab and production line, while Echemi classifies the business as Trader; no facility, license, in-house report, or named batch-release authority was found.
  • Direct-channel traceability and COA-authentication risk — high: The direct site has static Janoshik links, no public batch-to-vial lookup, no report ID above 133913 observed, and no printed vial-label commitment tying a received vial to a report.
  • Copycat and brand-confusion risk — high: The vendor warns of fake sites and impersonators, lookalike domains exist, and no authorized-reseller list, domain whitelist, signed COA system, or direct anti-counterfeit verifier was found.
  • Direct-payment and quality-remedy risk — medium: Direct purchases use T/T or crypto without online checkout or chargeback; the refund policy covers lost parcels, while the quality-refund promise lacks a public claim procedure.